Pfizer Inc. (NYSE:PFE) Shares Sold by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 1.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,343,771 shares of the biopharmaceutical company's stock after selling 16,000 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in Pfizer were worth $35,650,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $26,000. Gladius Capital Management LP lifted its stake in shares of Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 38,015 shares during the last quarter. Teachers Insurance & Annuity Association of America acquired a new position in shares of Pfizer in the 3rd quarter valued at $35,000. Joseph Group Capital Management lifted its stake in shares of Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 771 shares during the last quarter. Finally, Sierra Ocean LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $34,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on PFE. UBS Group cut their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Evercore ISI upgraded Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Guggenheim reiterated a "buy" rating and issued a $33.00 price objective on shares of Pfizer in a report on Monday, February 10th. Finally, StockNews.com downgraded Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Pfizer presently has an average rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Trading Up 1.6 %

PFE opened at $26.32 on Friday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a market cap of $149.14 billion, a P/E ratio of 18.66, a PEG ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business's 50-day simple moving average is $26.30 and its 200-day simple moving average is $27.41.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 EPS. The business's revenue for the quarter was up 24.7% on a year-over-year basis. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. Pfizer's dividend payout ratio is 121.99%.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.06% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.